J9179 Eribulin mesylate injection
Also known as: eribulin, Halaven
Intravenous injection of eribulin mesylate, a microtubule inhibitor derived from halichondrin.
In Plain Language
cancer cell-killing drug; breast cancer chemotherapy
Clinical Context
Used for metastatic breast cancer and liposarcoma, stabilizing microtubule structure.
RVU Information
CPT J9179 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.
Billing & Documentation
J-codes represent drugs administered by a healthcare provider (not self-administered). Documentation must include the drug name, dosage, route of administration, and medical necessity. Most payers require the National Drug Code (NDC) on the claim. Bill the appropriate administration code (96365-96379) in addition to the drug code.
Specialties
Frequently Asked Questions
What is CPT code J9179?
CPT J9179 (Eribulin mesylate injection) is a J Codes (Drugs) code. Intravenous injection of eribulin mesylate, a microtubule inhibitor derived from halichondrin.
How is J9179 administered?
CPT J9179 is administered by a healthcare provider, typically via injection or infusion. Used for metastatic breast cancer and liposarcoma, stabilizing microtubule structure. It is used by Oncology, Medical Oncology.
When is CPT J9179 used?
Used for metastatic breast cancer and liposarcoma, stabilizing microtubule structure.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.